Research ExplorerPublicationsAntibody response to SARS-CoV-2 for more than one year - kin...

Antibody response to SARS-CoV-2 for more than one year - kinetics and persistence of detection are predominantly determined by avidity progression and test design

Standard

Antibody response to SARS-CoV-2 for more than one year - kinetics and persistence of detection are predominantly determined by avidity progression and test design. / Scheiblauer, Heinrich; Nübling, Claudius Micha; Wolf, Timo; Khodamoradi, Yascha; Bellinghausen, Carla; Sonntagbauer, Michael; Esser-Nobis, Katharina; Filomena, Angela; Mahler, Vera; Maier, Thorsten Jürgen; Stephan, Christoph.

In: J CLIN VIROL, Vol. 146, 105052, 01.2022.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Scheiblauer, H, Nübling, CM, Wolf, T, Khodamoradi, Y, Bellinghausen, C, Sonntagbauer, M, Esser-Nobis, K, Filomena, A, Mahler, V, Maier, TJ & Stephan, C 2022, 'Antibody response to SARS-CoV-2 for more than one year - kinetics and persistence of detection are predominantly determined by avidity progression and test design', J CLIN VIROL, vol. 146, 105052. https://doi.org/10.1016/j.jcv.2021.105052

APA

Scheiblauer, H., Nübling, C. M., Wolf, T., Khodamoradi, Y., Bellinghausen, C., Sonntagbauer, M., Esser-Nobis, K., Filomena, A., Mahler, V., Maier, T. J., & Stephan, C. (2022). Antibody response to SARS-CoV-2 for more than one year - kinetics and persistence of detection are predominantly determined by avidity progression and test design. J CLIN VIROL, 146, [105052]. https://doi.org/10.1016/j.jcv.2021.105052

Vancouver

Scheiblauer H, Nübling CM, Wolf T, Khodamoradi Y, Bellinghausen C, Sonntagbauer M et al. Antibody response to SARS-CoV-2 for more than one year - kinetics and persistence of detection are predominantly determined by avidity progression and test design. J CLIN VIROL. 2022 Jan;146. 105052. https://doi.org/10.1016/j.jcv.2021.105052

Bibtex

@article{59541e444fe04263905373e8dd2314da,
title = "Antibody response to SARS-CoV-2 for more than one year - kinetics and persistence of detection are predominantly determined by avidity progression and test design",
abstract = "BACKGROUND: Antibody detection of SARS-CoV-2 requires an understanding of its variation, course, and duration.METHODS: Antibody response to SARS-CoV-2 was evaluated over 5-430 days on 828 samples across COVID-19 severity levels, for total antibody (TAb), IgG, IgA, IgM, neutralizing antibody (NAb), antibody avidity, and for receptor-binding-domain (RBD), spike (S), or nucleoprotein (N). Specificity was determined on 676 pre-pandemic samples.RESULTS: Sensitivity at 30-60 days post symptom onset (pso) for TAb-S/RBD, TAb-N, IgG-S, IgG-N, IgA-S, IgM-RBD, and NAb was 96.6%, 99.5%, 89.7%, 94.3%, 80.9%, 76.9% and 92.8%, respectively. Follow-up 430 days pso revealed: TAb-S/RBD increased slightly (100.0%); TAb-N decreased slightly (97.1%); IgG-S and IgA-S decreased moderately (81.4%, 65.7%); NAb remained positive (94.3%), slightly decreasing in activity after 300 days; there was correlation with IgG-S (Rs = 0.88) and IgA-S (Rs = 0.71); IgG-N decreased significantly from day 120 (15.7%); IgM-RBD dropped after 30-60 days (22.9%). High antibody avidity developed against S/RBD steadily with time in 94.3% of patients after 430 days. This correlated with persistent antibody detection depending on antibody-binding efficiency of the test design. Severe COVID-19 correlated with earlier and higher antibody response, mild COVID-19 was heterogeneous with a wide range of antibody reactivities. Specificity of the tests was ≥99%, except for IgA (96%).CONCLUSION: Sensitivity of anti-SARS-CoV-2 assays was determined by test design, target antigen, antibody avidity, and COVID-19 severity. Sustained antibody detection was mainly determined by avidity progression for RBD and S. Testing by TAb and for S/RBD provided the highest sensitivity and longest detection duration of 14 months so far.",
keywords = "Antibodies, Neutralizing, Antibodies, Viral, Antibody Formation, COVID-19, Humans, Immunoglobulin G, Immunoglobulin M, Kinetics, SARS-CoV-2, Spike Glycoprotein, Coronavirus",
author = "Heinrich Scheiblauer and N{\"u}bling, {Claudius Micha} and Timo Wolf and Yascha Khodamoradi and Carla Bellinghausen and Michael Sonntagbauer and Katharina Esser-Nobis and Angela Filomena and Vera Mahler and Maier, {Thorsten J{\"u}rgen} and Christoph Stephan",
note = "Copyright {\textcopyright} 2021. Published by Elsevier B.V.",
year = "2022",
month = jan,
doi = "10.1016/j.jcv.2021.105052",
language = "English",
volume = "146",
journal = "J CLIN VIROL",
issn = "1386-6532",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Antibody response to SARS-CoV-2 for more than one year - kinetics and persistence of detection are predominantly determined by avidity progression and test design

AU - Scheiblauer, Heinrich

AU - Nübling, Claudius Micha

AU - Wolf, Timo

AU - Khodamoradi, Yascha

AU - Bellinghausen, Carla

AU - Sonntagbauer, Michael

AU - Esser-Nobis, Katharina

AU - Filomena, Angela

AU - Mahler, Vera

AU - Maier, Thorsten Jürgen

AU - Stephan, Christoph

N1 - Copyright © 2021. Published by Elsevier B.V.

PY - 2022/1

Y1 - 2022/1

N2 - BACKGROUND: Antibody detection of SARS-CoV-2 requires an understanding of its variation, course, and duration.METHODS: Antibody response to SARS-CoV-2 was evaluated over 5-430 days on 828 samples across COVID-19 severity levels, for total antibody (TAb), IgG, IgA, IgM, neutralizing antibody (NAb), antibody avidity, and for receptor-binding-domain (RBD), spike (S), or nucleoprotein (N). Specificity was determined on 676 pre-pandemic samples.RESULTS: Sensitivity at 30-60 days post symptom onset (pso) for TAb-S/RBD, TAb-N, IgG-S, IgG-N, IgA-S, IgM-RBD, and NAb was 96.6%, 99.5%, 89.7%, 94.3%, 80.9%, 76.9% and 92.8%, respectively. Follow-up 430 days pso revealed: TAb-S/RBD increased slightly (100.0%); TAb-N decreased slightly (97.1%); IgG-S and IgA-S decreased moderately (81.4%, 65.7%); NAb remained positive (94.3%), slightly decreasing in activity after 300 days; there was correlation with IgG-S (Rs = 0.88) and IgA-S (Rs = 0.71); IgG-N decreased significantly from day 120 (15.7%); IgM-RBD dropped after 30-60 days (22.9%). High antibody avidity developed against S/RBD steadily with time in 94.3% of patients after 430 days. This correlated with persistent antibody detection depending on antibody-binding efficiency of the test design. Severe COVID-19 correlated with earlier and higher antibody response, mild COVID-19 was heterogeneous with a wide range of antibody reactivities. Specificity of the tests was ≥99%, except for IgA (96%).CONCLUSION: Sensitivity of anti-SARS-CoV-2 assays was determined by test design, target antigen, antibody avidity, and COVID-19 severity. Sustained antibody detection was mainly determined by avidity progression for RBD and S. Testing by TAb and for S/RBD provided the highest sensitivity and longest detection duration of 14 months so far.

AB - BACKGROUND: Antibody detection of SARS-CoV-2 requires an understanding of its variation, course, and duration.METHODS: Antibody response to SARS-CoV-2 was evaluated over 5-430 days on 828 samples across COVID-19 severity levels, for total antibody (TAb), IgG, IgA, IgM, neutralizing antibody (NAb), antibody avidity, and for receptor-binding-domain (RBD), spike (S), or nucleoprotein (N). Specificity was determined on 676 pre-pandemic samples.RESULTS: Sensitivity at 30-60 days post symptom onset (pso) for TAb-S/RBD, TAb-N, IgG-S, IgG-N, IgA-S, IgM-RBD, and NAb was 96.6%, 99.5%, 89.7%, 94.3%, 80.9%, 76.9% and 92.8%, respectively. Follow-up 430 days pso revealed: TAb-S/RBD increased slightly (100.0%); TAb-N decreased slightly (97.1%); IgG-S and IgA-S decreased moderately (81.4%, 65.7%); NAb remained positive (94.3%), slightly decreasing in activity after 300 days; there was correlation with IgG-S (Rs = 0.88) and IgA-S (Rs = 0.71); IgG-N decreased significantly from day 120 (15.7%); IgM-RBD dropped after 30-60 days (22.9%). High antibody avidity developed against S/RBD steadily with time in 94.3% of patients after 430 days. This correlated with persistent antibody detection depending on antibody-binding efficiency of the test design. Severe COVID-19 correlated with earlier and higher antibody response, mild COVID-19 was heterogeneous with a wide range of antibody reactivities. Specificity of the tests was ≥99%, except for IgA (96%).CONCLUSION: Sensitivity of anti-SARS-CoV-2 assays was determined by test design, target antigen, antibody avidity, and COVID-19 severity. Sustained antibody detection was mainly determined by avidity progression for RBD and S. Testing by TAb and for S/RBD provided the highest sensitivity and longest detection duration of 14 months so far.

KW - Antibodies, Neutralizing

KW - Antibodies, Viral

KW - Antibody Formation

KW - COVID-19

KW - Humans

KW - Immunoglobulin G

KW - Immunoglobulin M

KW - Kinetics

KW - SARS-CoV-2

KW - Spike Glycoprotein, Coronavirus

U2 - 10.1016/j.jcv.2021.105052

DO - 10.1016/j.jcv.2021.105052

M3 - SCORING: Journal article

C2 - 34920374

VL - 146

JO - J CLIN VIROL

JF - J CLIN VIROL

SN - 1386-6532

M1 - 105052

ER -